{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:09:18Z","timestamp":1778962158929,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010585","name":"Gobierno Vasco Departamento de Salud","doi-asserted-by":"publisher","award":["202011142"],"award-info":[{"award-number":["202011142"]}],"id":[{"id":"10.13039\/501100010585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.remnie.2024.500089","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T18:01:03Z","timestamp":1734717663000},"page":"500089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of dosimetry and clinical variables in treatments of neuroendocrine tumours with [177Lu]Lu-DOTA-TATE"],"prefix":"10.1016","volume":"44","author":[{"given":"P.","family":"M\u00ednguez Gabi\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Monserrat Fuertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Santos Zorrozua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Esteban Figueruelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Astudillo Sarmiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pe\u00f1a Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vinagre P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rode\u00f1o Ortiz de Zarate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.L.","family":"Fern\u00e1ndez Tercero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2024.500089_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0010","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0015","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","article-title":"Efficacy of [177Lu]Lu\u2011DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study","volume":"50","author":"Mitjavila","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0020","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-014-2824-5","article-title":"The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy","volume":"41","author":"Strigari","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"Ilan","year":"2015","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.remnie.2024.500089_bib0030","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2967\/jnumed.123.266991","article-title":"Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE","volume":"65","author":"Warfvinge","year":"2024","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.remnie.2024.500089_bib0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.123.267023","article-title":"Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE: one step closer to personalized medicine","volume":"65","author":"Hebert","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0040","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177 Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","author":"Sundl\u00f6v","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0045","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","article-title":"Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases","volume":"60","author":"Hagmarker","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0050","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundl\u00f6v","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.121.262069","article-title":"Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE","volume":"63","author":"Roth","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050962","article-title":"Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms","volume":"13","author":"Jahn","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.remnie.2024.500089_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"MIRD pamphlet No. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.remnie.2024.500089_bib0080","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acd982","article-title":"Activity recovery for differently shaped objects in quantitative SPECT","volume":"68","author":"M\u00ednguez Gabi\u00f1a","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.remnie.2024.500089_bib0085","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0090","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","article-title":"Feasibility of single-time-point dosimetry for radiopharmaceutical therapies","volume":"62","author":"Hou","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0095","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","volume":"45","author":"Gear","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621641","article-title":"Tumor control probability modeling for radiation therapy of keratinocyte carcinoma","volume":"11","author":"Prior","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.remnie.2024.500089_bib0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semradonc.2024.04.004","article-title":"The effects of radiation dose heterogeneity on the tumor microenvironment and anti-tumor immunity","volume":"34","author":"Takashima","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.remnie.2024.500089_bib0110","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1088\/0031-9155\/61\/6\/2532","article-title":"Biologically effective dose in fractionated molecular radiotherapy\u2014application to treatment of neuroblastoma with (131)I-mIBG","volume":"61","author":"M\u00ednguez","year":"2016","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.remnie.2024.500089_bib0115","series-title":"ICRU report 96, dosimetry-guided radiopharmaceutical therapy","year":"2022"},{"key":"10.1016\/j.remnie.2024.500089_bib0120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2967\/jnumed.123.266843","article-title":"SPECT\/CT image-derived absorbed dose to red marrow correlates with hematologic toxicity in patients treated with [177Lu]Lu-DOTATATE","volume":"65","author":"Blakkisrud","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0125","unstructured":"COUNCIL DIRECTIVE 2013\/59\/EURATOM of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89\/618\/Euratom, 90\/641\/Euratom, 96\/29\/Euratom, 97\/43\/Euratom and 2003\/122\/Euratom. Official Journal of the European Union; 2014. p. 1\u201373."},{"key":"10.1016\/j.remnie.2024.500089_bib0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-020-05038-9","article-title":"EANM position paper on article 56 of the Council Directive 2013\/59\/Euratom (basic safety standards) for nuclear medicine therapy","volume":"48","author":"Konijnenberg","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2023.103166","article-title":"EFOMP policy statement NO. 19: dosimetry in nuclear medicine therapy - Molecular radiotherapy","author":"Sj\u00f6green-Gleisner","year":"2023","journal-title":"Phys Med"},{"key":"10.1016\/j.remnie.2024.500089_bib0140","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remnie.2024.500089_bib0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00259-022-05934-2","article-title":"An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine","volume":"50","author":"Pouget","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2024.500089_bib0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41571-022-00709-y","article-title":"Predicting tumour radiosensitivity to deliver precision radiotherapy","volume":"20","author":"Price","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808924001174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808924001174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:47:04Z","timestamp":1778960824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808924001174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2253808924001174"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2024.500089","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of dosimetry and clinical variables in treatments of neuroendocrine tumours with [177Lu]Lu-DOTA-TATE","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2024.500089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500089"}}